메디채널

주메뉴 바로가기
본문 바로가기

기상청 제공

닫기

라이프

FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)

Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1] AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19) in IV formulation [1] INCHEON, South Korea, Aug. 6, 2025 -- Celltrion, Inc. today announced that
- 김갑성 기자
- 2025-08-06 20:00
Continuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors

BRADENTON, Fla., Aug. 6, 2025 -- Continuity Biosciences, a company pioneering next-generation combination product drug delivery, today announced the appointment of two highly distinguished leaders to its Board of Directors: Josephine M. Torrente, Director at Hyman, Phelps & McNamara, P.C., and Dr. Joseph M. DeSimone, serial entrepreneur and professor at Stanford University. These appointments mark a significant step forward in Continuity's mission to advance transformative drug delivery technologies, supported by world-class regulatory expertise and materials science innovation.&n
- 김갑성 기자
- 2025-08-06 20:00
컨티뉴이티 바이오사이언스, 이사회에 조세핀 토렌테, 조지프 디시몬 영입

브레이든턴, 플로리다, 2025년 8월 6일 -- 차세대 복합 약물 전달 분야의 선도 기업인 컨티뉴이티 바이오사이언스(Continuity Biosciences)가 이사회에 두 명의 저명한 인사를 영입했다고 발표했다. 새로 합류한 인사는 조세핀 M. 토렌테(Josephine M. Torrente) 하이먼, 펠프스 & 맥나마라(Hyman, Phelps & McNamara, P.C.) 이사와 조지프 M. 디시몬(Dr. Joseph M. DeSimone) 스탠퍼드대학교 교수이자 연쇄 창업가다. 이번 선임은 세계적인 규제 전문성과 재료과학 혁신을 바탕으로 혁신적인 약물 전달 기술을 발전시키려는 콘티뉴이티의 사명에 있어 중요한 진전으로 평가된다. 조세핀 M. 토렌테 현직: 미국 최대 규모의 FDA 규제 전문 법률 회사인 하이먼, 펠프스 & 맥나마라(Hyman, Phelps & McNamara, P.C.) 이사 경력: 30년 이상 제약 및 바이오 기업을 대상으로 FDA 규제 전략, 제품 개발, 전주기 관리 등에 대해 자문 전략적 기여: 토렌테 이사의 깊이 있는 규제 통찰력을 통해 회사가
- 김갑성 기자
- 2025-08-06 20:00
The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients SHANGHAI, Aug. 6, 2025 -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment
- 김갑성 기자
- 2025-08-06 19:02
Ductal Carcinoma In Situ Discovery from Gynecomastia Surgery by Dr Ivan Puah

[ 메디채널 김갑성 기자 ] Gynecomastia can indicate underlying health concerns, including cancer, and surgery provides an opportunity to examine tissues for abnormalities. Early detection saves lives. SINGAPORE, Aug. 6, 2025 -- Dr Ivan Puah, an MOH-accredited liposuction doctor at Amaris B. Clinic, with decades of experience in male chest contouring and gynecomastia surgery, emphasises the critical significance of adhering to rigorous surgical protocols and conducting comprehensive diagnostics. This includes the essential practice of sending every case of gynecomastia surgery for thorough hist
- 김갑성 기자
- 2025-08-06 17:28
Ductal Carcinoma In Situ Discovery from Gynecomastia Surgery by Dr Ivan Puah

[ 메디채널 김갑성 기자 ] Gynecomastia can indicate underlying health concerns, including cancer, and surgery provides an opportunity to examine tissues for abnormalities. Early detection saves lives. SINGAPORE, Aug. 6, 2025 -- Dr Ivan Puah, an MOH-accredited liposuction doctor at Amaris B. Clinic, with decades of experience in male chest contouring and gynecomastia surgery, emphasises the critical significance of adhering to rigorous surgical protocols and conducting comprehensive diagnostics. This includes the essential practice of sending every case of gynecomastia surgery for thorough hist
- 김갑성 기자
- 2025-08-06 16:38
Thyseed Newborn Baby Bottle with Bottom Vent Design: Clinically Proven to Reduce Colic and Spit-up by 30%

[ 메디채널 김갑성 기자 ] New anti-colic system delivers clinically tested relief for newborn digestive discomfort BEIJING, Aug. 6, 2025 -- Thyseed, an established name in global infant care, has announced the launch of its newborn baby bottle featuring proprietary bottom vent technology for global markets. Clinical trials confirm that this design reduces colic and spit-up by more than 30% among infants aged 0-3 months. The product is fully certified by the US FDA and relevant EU authorities, with all components passing more than 40 safety and performance tests by Swiss testing agency SGS. It
- 김갑성 기자
- 2025-08-06 14:38
Thyseed Is Set to Support Southeast Asian Families with Safer Infant Feeding Solutions, Powered by Medical-Grade Technology

BEIJING, Aug. 6, 2025 -- Thyseed, an established name in global infant care, recently announced plans to introduce its premium, safety-certified feeding solutions to Southeast Asian households in 2025. With an established presence in the United States, Russia, and mainland China, Thyseed is committed to extending its industry-leading safety standards to new markets. Since its inception, Thyseed has championed a commitment to safeguarding infants from their earliest interactions with feeding products in a move to transform infant feeding safety through profound consumer insights and gro
- 김갑성 기자
- 2025-08-06 13:52
Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced the Taiwan Food and Drug Administration (TFDA) has approved the supplementary application for NEFECON®. NEFECON® is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression, irrespective of proteinuria levels. With this label u
- 김갑성 기자
- 2025-08-06 13:09
4 in 5 APAC consumers take health supplements but half lack confidence in making good supplement choices - Herbalife survey

Preventive health trend driving need for credible and trusted sources of information HONG KONG, Aug. 6, 2025 -- Herbalife, a premier health and wellness company and community, today released findings from its 2025 Asia Pacific Responsible Supplementation Survey, revealing that while there is widespread use of health supplements in Asia Pacific (APAC), many lack the confidence to make good supplement decisions. Four in five (80%) consumers in the region take health supplements regularly, but only half (50%) expressed confidence in their ability to make responsible supplement cho
- 김갑성 기자
- 2025-08-06 11:00

이전

21 22 23 24 25 26 27 28 29 30

많이 본 기사

최근기사

2025-09-05_FRI

발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.

UPDATE: 2025년 09월 05일 15시 40분